Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a note from CEO Jim Joyce detailing CardioDialysis, a novel medical device designed to reduce major adverse cardiovascular events (MACE). Cardiovascular disease remains the leading cause of death worldwide, and current therapies like statins reduce MACE by only about 25%. In contrast, lipoprotein apheresis devices that filter LDL-C and Lipoprotein(a) can reduce MACE by 75-95%, according to the American Heart Association. However, these devices are complex and require specialized centers, limiting their use.
CardioDialysis integrates plasma separation and therapeutic adsorption into a single device that can be deployed on dialysis machines already present in over 5,000 hospitals and 7,500 dialysis clinics in the United States. This addresses the accessibility issue, as existing systems like the Kaneka LIPOSORBER require multiple components and are available at fewer than 60 specialized apheresis centers nationwide. CardioDialysis processes the bloodstream more efficiently and does not need replacement fluids or additional pumps.
The device targets a broader range of cardiovascular disease drivers, including inflammatory mediators that fuel disease progression, while lowering cholesterol-transporting lipoproteins. Given that 15-20% of MACE result in death, successful clinical advancement of CardioDialysis could save thousands of lives annually. The company is also exploring applications in sepsis, viral infections, and neuroinflammatory disorders.
For more information, visit SigynTherapeutics.com.
